Iovance Biotherapeutics to Participate at November Investor Conferences
November 13 2018 - 8:01AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that company management will present and participate in the
following conferences in November:
- Credit Suisse 27th Annual Healthcare
Conference in Scottsdale, AZ on Tuesday, November 13,
2018.
- Jefferies Global Healthcare Conference in
London, United Kingdom on Thursday, November 15, 2018 at 4:00 p.m.
GMT.
- Evercore ISI HealthCONx Conference in Boston,
MA on Tuesday, November 27, 2018 at 11:20 a.m. ET.
A live audio webcast of the Jefferies and Evercore ISI
conference presentations will be available by visiting the
Investors section of Iovance Biotherapeutics' website
at http://ir.iovance.com/. A replay of the webcasts will be
archived on Iovance Biotherapeutics’ website for 30 days following
the presentations.
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The company's lead product
candidate is an adoptive cell therapy using TIL technology being
investigated for the treatment of patients with metastatic
melanoma, recurrent and/or metastatic squamous cell carcinoma of
the head and neck, recurrent, metastatic or persistent cervical
cancer and locally advanced or metastatic non-small cell lung
cancer. For more information, please
visit http://www.iovance.com.
Investor Relations Contact: Sarah McCabeStern
Investor Relations, Inc.212-362-1200sarah@sternir.com
Media Relations Contact:John CapodannoFTI
Consulting 212-850-5705john.capodanno@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024